Ginger Clark

Ginger Clark, M.D., M.S.

Program Director & Associate Professor

Department: MD-GASTROENTERLOGY-LIVER
Business Email: clarkvc@medicine.ufl.edu

Accomplishments

Exemplary Teacher Award
2019 · College of Medicine

Teaching Profile

Courses Taught
2019-2021
BMS6634 GI and Hepatology
2016-2018
MDT7200 Elect Top/Medicine
2018
MDC6001 Intro Clin Practice
2018
PAS5160 Gastroenterology

Clinical Profile

Specialties
  • Gastroenterology
  • Transplant Hepatology

Publications

2022
Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency.
Gut. 71(2):415-423 [DOI] 10.1136/gutjnl-2020-323729. [PMID] 33632708.
2021
Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study.
Journal of hepatology. 75(5):1026-1033 [DOI] 10.1016/j.jhep.2021.06.019. [PMID] 34166722.
2021
Quantitative measurement of the histological features of alpha-1 antitrypsin deficiency-associated liver disease in biopsy specimens.
PloS one. 16(8) [DOI] 10.1371/journal.pone.0256117. [PMID] 34398915.
2019
Managing the Alpha-1 patient in the ICU: Adapting broad critical care strategies in AATD.
Journal of critical care. 54:212-219 [DOI] 10.1016/j.jcrc.2019.08.027. [PMID] 31614323.
2019
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 67(2):303-311 [DOI] 10.1136/jim-2018-000864. [PMID] 30309884.
2018
Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort.
Journal of hepatology. 69(6):1357-1364 [DOI] 10.1016/j.jhep.2018.08.005. [PMID] 30138687.
2018
Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 16(4):558-566.e2 [DOI] 10.1016/j.cgh.2017.12.001. [PMID] 29223443.
2017
Evaluating the Efficacy of a Registry linked to a Consent to Re-Contact Program and Communication Strategies for Recruiting and Enrolling Participants into Clinical Trials.
Contemporary clinical trials communications. 8:62-66 [DOI] 10.1016/j.conctc.2017.08.005. [PMID] 29503877.
2017
Liver Transplantation in Alpha-1 Antitrypsin Deficiency
Clinics in Liver Disease. 21(2):355+-365 [DOI] 10.1016/j.cld.2016.12.008.
2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
The lancet. Gastroenterology & hepatology. 2(10):716-726 [DOI] 10.1016/S2468-1253(17)30246-7. [PMID] 28818518.
2014
Cyproheptadine-Induced Acute Liver Failure.
ACG case reports journal. 1(4):212-213 [PMID] 25580444.
2013
An Unusual Case of Gastrointestinal Bleeding
American Journal of Gastroenterology. 108(1)
2013
CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant.
Liver international : official journal of the International Association for the Study of the Liver. 33(1):72-8 [DOI] 10.1111/liv.12013. [PMID] 23107586.
2013
Hepatic preservation injury: severity of hepatitis C recurrence and survival after liver transplantation.
Digestive diseases and sciences. 58(5):1403-9 [DOI] 10.1007/s10620-012-2521-9. [PMID] 23306846.
2013
Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Hepatology research : the official journal of the Japan Society of Hepatology. 43(7):757-64 [DOI] 10.1111/hepr.12019. [PMID] 23193965.
2013
New therapeutic strategies in HCV: second-generation protease inhibitors.
Liver international : official journal of the International Association for the Study of the Liver. 33 Suppl 1:80-4 [DOI] 10.1111/liv.12061. [PMID] 23286850.
2013
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Alimentary pharmacology & therapeutics. 37(1):91-7 [DOI] 10.1111/apt.12098. [PMID] 23094860.
2013
Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma.
Oncology reports. 29(4):1259-67 [DOI] 10.3892/or.2013.2290. [PMID] 23426976.
2012
Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation.
American journal of clinical oncology. 35(4):345-50 [DOI] 10.1097/COC.0b013e31821631f6. [PMID] 21552101.
2012
Incidentally Discovered Hcc (Ihcc) in Explant Liver- Clinical and Histopathologic Features and Outcome
Higher Education Policy. 56:476A-477A
2012
Liver test results do not identify liver disease in adults with α(1)-antitrypsin deficiency.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 10(11):1278-83 [DOI] 10.1016/j.cgh.2012.07.007. [PMID] 22835581.
2012
The Impact of Pre Transplant Transarterial Therapy in Hepatocellular Carcinoma
Higher Education Policy. 56:458A-459A
2012
The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.
Liver international : official journal of the International Association for the Study of the Liver. 32 Suppl 1(0 1):103-7 [DOI] 10.1111/j.1478-3231.2011.02711.x. [PMID] 22212579.
2011
A Sustained Viral Response Dramatically Improves Survival in Patients With Hepatitis C Infection After Liver Transplant
. 54
2011
Alt Abnormalities in Adults With Alpha-1 Antitrypsin Deficiency
. 54
2011
Antiviral Effect of Sorafenib in Hcv Related Hepatocellular Carcinoma
Higher Education Policy. 54
2011
Klatskin Tumor- Clinical Outcome and Prognostic Factors
Higher Education Policy. 54
2011
Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature.
Hepatology international. 5(3):808-13 [DOI] 10.1007/s12072-011-9260-4. [PMID] 21484124.
2011
Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
Alimentary pharmacology & therapeutics. 33(2):235-42 [DOI] 10.1111/j.1365-2036.2010.04512.x. [PMID] 21083674.
2011
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Alimentary pharmacology & therapeutics. 34(2):205-13 [DOI] 10.1111/j.1365-2036.2011.04697.x. [PMID] 21605146.
2010
The Impact of Preservation Injury On Accelerated Hepatitis C Recurrence After Liver Transplantation
Higher Education Policy. 52
2010
The Impact of Transarterial Therapy in Recurrent Hepatocellular Carcinoma After Liver Transplant
Higher Education Policy. 52
2010
The Impact of Transarterial Therapy in Recurrent Hepatocellular Carcinoma After Liver Transplant
Higher Education Policy. 52
2010
The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study.
Digestive diseases and sciences. 55(1):196-203 [DOI] 10.1007/s10620-009-0981-3. [PMID] 19798576.
2010
Treatment of chronic hepatitis C in patients with Crohn’s disease.
Gastroenterology & hepatology. 6(8):527-8 [PMID] 20978558.
2009
Fenofibrate Improves Liver Biochemistries in Primary Biliary Cirrhosis
Higher Education Policy. 50
2009
Novel interferons for treatment of hepatitis C virus.
Clinics in liver disease. 13(3):351-63 [DOI] 10.1016/j.cld.2009.05.004. [PMID] 19628153.
2009
The natural history of hepatitis C cirrhosis after liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 15(9):1063-71 [DOI] 10.1002/lt.21784. [PMID] 19718647.
2008
The Natural History of Hcv-Related Cirrhosis After Liver Transplantation
Journal of Hepatology. 48 [DOI] 10.1016/S0168-8278(08)60003-3.
2007
What is the influence of long-term ursodeoxycholic acid therapy in patients with primary biliary cirrhosis?
Nature clinical practice. Gastroenterology & hepatology. 4(4):188-9 [PMID] 17290236.

Grants

Nov 2021 ACTIVE
A Phase 1, Open-Label Study Evaluating the Liver Tissue Concentration of VX-864 in Subjects Who Have the PiZZ Genotype and Healthy Subjects
Role: Principal Investigator
Funding: GREENPHIRE via VERTEX PHARMACEUTICALS
Jul 2021 ACTIVE
The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
Role: Principal Investigator
Funding: NOVO NORDISK
Feb 2021 ACTIVE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Role: Principal Investigator
Funding: SC LIVER RESEARCH CONSORTIUM
May 2020 ACTIVE
Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDDK
Jun 2019 – Mar 2022
Investigation of efficacy and safety of semaglutide s.c. once-weekly versus placebo in subjects with non-alcoholic steatohepatitis and compensated liver cirrhosis
Role: Principal Investigator
Funding: NOVO NORDISK
Jun 2019 ACTIVE
A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency (AATD)
Role: Principal Investigator
Funding: AGILITY CLINICAL INC via ARROWHEAD PHARMACEUTICALS
Dec 2016 ACTIVE
TARGET-PBC "A 5-year Longitudinal Observational Study of Patients with Primary Biliary Cholangitis"
Role: Principal Investigator
Funding: TARGET PHARMASOLUTIONS dba TARGET RWE
Aug 2016 – Mar 2022
Fund 214 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis
Role: Principal Investigator
Funding: LABCORP DRUG DEVELOPMENT via GENFIT SA
Aug 2016 – Jun 2022
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis
Role: Principal Investigator
Funding: SC LIVER RESEARCH CONSORTIUM via GENFIT SA
Apr 2016 – Aug 2022
214 Fund A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR 12 WEEKS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC)
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via NGM BIOPHARMACEUTICALS INC
Apr 2016 – Aug 2022
A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF EMRICASAN (IND-6556) AN ORAL CASPASE INHIBITOR IN..
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via CONATUS PHARMACEUTICALS
Dec 2015 – Dec 2018
a 12 week double blind randomized placebo-controlled
Role: Principal Investigator
Funding: CYMABAY THERAPEUTICS
Mar 2015 – Mar 2018
LAL-CSS01 A STUDY TO IDENTIFY THE FREQUENCY OF LYSOSOMAL ACID LIPASE DEFICIENCY IN AT-RISK PATIENT POPULATIONS
Role: Principal Investigator
Funding: SYNAGEVA BIOPHARMA
Nov 2014 ACTIVE
CLARK PAYROLL OPERATING ACCOUNT
Role: Principal Investigator
Funding: 214 OPERATING ACCOUNT
Jan 2013 – Jan 2016
00087226 Clark, V GENFIT GFT505-212-7 'A Study to Evaluate the Efficacy and Safety of GFT505 Once Daily on Steatohepatitis in Patients with (NASH) A Multicentre, Rand DB, Placebo-Controlled Study, with an Adaptive Design
Role: Principal Investigator
Funding: PREMIER RESEARCH INTERNATIONAL
Jul 2007 – Aug 2016
Clinical and Translational Science Institute
Role: Project Manager
Funding: UF RESEARCH FOU

Contact Details

Emails:
Fellowship Coordinator I:
Addresses:
Business Mailing:
PO Box 100214
GAINESVILLE FL 32610
Business Street:
1329 SW 16TH ST STE 5251
GAINESVILLE FL 32608